DiscoverOncology On The GoS2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
S2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

S2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

Update: 2022-05-20
Share

Description

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.



As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in Durham, North Carolina, about recent updates in the use of proteasome inhibitors for patients with multiple myeloma.



In the video series, Richardson and Gasparetto discussed the following:









Be sure to tune in to other videos in the CancerNetwork® Between the Lines™ series.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

S2 Ep25: Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

CancerNetwork